Icosavax Inc. (ICVX) Files up to $100M IPO

Icosavax Inc. (ICVX) files for up to $100,000,000 IPO. The stock will list on the NASDAQ under the ticker 'ICVX'.

The company describes itself as: "We are a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which we believe will induce broad, robust, and durable protection against the specific viruses targeted. Our pipeline includes vaccine candidates targeting some of the most prevalent viral causes of pneumonia. We are developing these candidates for older adults, a patient population with high unmet need. Our vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV)."

Jefferies, Cowen, Evercore ISI and William Blair will serve as underwriters.

You May Also Be Interested In

• Tailored Brands files for IPO on Nasdaq
• Timwood Holdings files for 5.6M share IPO at $4-$6/sh
• SK hynix lists American depositary receipts on Nasdaq